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Simple Summary: Gliomas represent the vast majority of primary brain tumours and are of significant
medical importance due to the poor clinical course of affected patients. The isocitrate dehydrogenase
1 (IDH1) mutation is associated with improved prognosis, compared to patients with IDH1-wildtype
lesions of the same stage. In this proof-of-concept study, Fourier transform infrared spectroscopy
was used to determine the IDH1 molecular status in fixed glioma sections. Classification algorithms
successfully distinguished the two IDH1 classes with high accuracies (>80%). Knowledge of the IDH1
status would be beneficial, as maximum resection may be preferred in patients with IDH1-mutant
gliomas, whilst a more limited resection can be best for IDH1-wildtype gliomas. Furthermore, we
examined blood serum in an attempt to identify the biomolecular alterations caused by the IDH1
mutation. Non-invasive approaches that can detect the molecular status may guide some patients to
an alternative treatment prior to surgery.
Abstract: Mutations in the isocitrate dehydrogenase 1 (IDH1) gene are found in a high proportion of
diffuse gliomas. The presence of the IDH1 mutation is a valuable diagnostic, prognostic and predictive
biomarker for the management of patients with glial tumours. Techniques involving vibrational
spectroscopy, e.g., Fourier transform infrared (FTIR) spectroscopy, have previously demonstrated
analytical capabilities for cancer detection, and have the potential to contribute to diagnostics.
The implementation of FTIR microspectroscopy during surgical biopsy could present a fast, label-free
method for molecular genetic classification. For example, the rapid determination of IDH1 status in a
patient with a glioma diagnosis could inform intra-operative decision-making between alternative
surgical strategies. In this study, we utilized synchrotron-based FTIR microanalysis to probe tissue
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microarray sections from 79 glioma patients, and distinguished the positive class (IDH1-mutated)
from the IDH1-wildtype glioma, with a sensitivity and specificity of 82.4% and 83.4%, respectively.
We also examined the ability of attenuated total reflection (ATR)-FTIR spectroscopy in detecting
the biomolecular events and global epigenetic and metabolic changes associated with mutations in
the IDH1 enzyme, in blood serum samples collected from an additional 72 brain tumour patients.
Centrifugal filtration enhanced the diagnostic ability of the classification models, with balanced
accuracies up to ~69%. Identification of the molecular status from blood serum prior to biopsy could
further direct some patients to alternative treatment strategies.
Keywords: biophotonics; infrared; imaging; cancer; histopathology; biofluids; glioma
1. Introduction
Somatic mutations in the human cytosolic isocitrate dehydrogenase 1 (IDH1) gene are a frequent
feature observed in gliomas. The IDH1 mutation tends to occur in the early stages of gliomagenesis,
hence it is most commonly found in low-grade gliomas, diffuse astrocytoma and oligodendrogliomas [1],
but is less common (10%) in primary glioblastoma (GBM) [2,3], except where the GBM develops from a
previously diagnosed diffuse or anaplastic astrocytoma (>80%) [4,5]. Consequently, the IDH1 mutation
serves as a valuable diagnostic marker (Table 1) by assisting in the differentiation of tumour entities
that are often indistinguishable through histopathological analysis alone, but have different treatments
and prognostic profiles [5].
Table 1. Common genetic and chromosomal aberrations associated with the major glioma subtypes [6].
Abbreviations defined below the table.
Glioma Entity WHO Grade IDH1 Mutation Additional Associated Alterations
Pilocytic astrocytoma I Extremely rare BRAF, KRAS, NF1, FGFR1
Diffuse astrocytoma II Common IDH2, TP53, ATRX, LOH 17p
Anaplastic astrocytoma III Common IDH2, TP53, ATRX, LOH 17p
Oligodendroglioma II Majority of cases IDH2, 1p/19q co-deletion
Anaplastic
oligodendroglioma III Majority of cases IDH2, 1p/19q co-deletion
Glioblastoma (primary) IV Rare TERT, PTEN, TP53, MGMThypermethylation, EGFR, 7+/10−
Glioblastoma
(secondary) IV Extremely Common IDH2, TP53, ATRX, LOH 17p
NF1, neurofibromatosis type 1; FGFR1, fibroblast growth receptor 1; IDH2, isocitrate dehydrogenase 2; TP53, tumour
suppressor protein 53; ATRX, alpha thalassemia/mental retardation syndrome X-linked mutation; LOH 17p, loss of
heterozygosity on chromosome 17; TERT, telomerase reverse transcriptase; PTEN, phosphatase and tensin homolog;
MGMT, O(6)-methlyguanine-DNA-methyltransferase; EGFR, epidermal growth factor receptor, 7+/10−, gain of
chromosome 7 and loss of chromosome 10. Italics: Genes.
The normal function of the IDH1 enzyme is to convert isocitrate to α-ketoglutarate (αKG).
Cancer-associated mutations in IDH1 inactivate this standard enzymatic activity, but enable a
neomorphic conversion of αKG to the oncometabolite 2-hydroxyglutarate (2HG) [7,8]. This results
in an accumulation of 2HG in the glioma cells, which is thought to drive oncogenic activity and
tumorigenesis [9]. The vast majority (~90%) of IDH1 mutations involve transitions in codon 132, where
the arginine residue is replaced by histidine (R132H-IDH1) [2]. Patients who have this IDH1 mutation
in their glioma have a significantly better prognosis compared to those with IDH1-wildtype lesions of
the same histologic grade [10,11]. For example, those with an IDH-mutant GBM tend to have a better
predicted prognosis than patients with a lower-grade IDH-wildtype astrocytoma [4,12].
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The presence of R132H-IDH1 can be established through immunohistochemistry (IHC) by applying
the mIDH1R132H antibody to resected glioma tissue [13]. IHC depends on invasive biopsy, with
inherent risk for the patient. The R132H-IDH1 expression may be present only in a fraction of tumour
cells in some diffuse gliomas, therefore a negative result does not necessarily exclude a glial lesion as
the concentration of immuno-positive diffuse astrocytomas ranges between 50% and 70% [14]. Thus,
several sections of tumour often need to be biopsied for a reliable result. Likewise, false positives are
occasionally observed because of non-specific background staining, and the regional heterogeneity of
R132H-IDH1 expression can cause doubt in the diagnosis, which may necessitate confirmatory genetic
analysis [15].
The development of a simple, rapid and label-free diagnostic tool for IDH1 detection would be
transformative for molecular diagnosis. Analytical techniques involving vibrational spectroscopy
have great potential for diagnosing disease states, namely infrared and Raman spectroscopy [16–18].
In particular, Fourier transform infrared (FTIR) spectroscopy has been shown to be valuable for the
detection of various cancers, such as breast, lung, colorectal, ovarian and prostate cancer [19–26], since
it can probe the biochemical composition of normal and pathological tissue and generate the fingerprint
structure of several biomolecular components, such as proteins, lipids and nucleic material [27,28].
Several studies have looked into diagnosing brain lesions, utilizing Raman spectroscopy [29–32].
Likewise, FTIR can detect and stratify brain malignancies through the analysis of resected tissue
sections, mainly focused on transmission techniques [33–36]. On the other hand, attenuated total
reflection (ATR)-FTIR is well-suited to biological fluids, such as blood serum [37,38]. The technique
provides for the qualitative interrogation of all infrared active macromolecular constituents of blood
serum, and it is well established that biomolecular imbalances in biofluids can give an indication
of disease states [28]. The plethora of spectroscopic studies highlight the capability of FTIR to
become a powerful tool in the diagnostic field [39]. Uckermann et al. recently indicated FTIR
could be suitable in identifying mutated IDH1 expression, through the analysis of 34 frozen brain
tissue cryosections and 64 fresh unfixed glioma biopsies [40]. Despite some promising results, the
spectra of both the cryosections and fresh tissue biopsies demonstrated high inter-patient variability.
The variance in the fresh tissue analysis may have been accentuated by the use of ATR-FTIR, which
only interrogates the region of the tissue sample that is in contact with the internal reflection element
(IRE), so it can be difficult to ensure that the sampling area being examined is representative of the
tumour. Uckermann et al. proposed that further work would be required to fully evaluate the ability
of the technique in the application of detecting the IDH1 mutation and other potential biomarkers.
Synchrotron radiation-based FTIR (SR-FTIR) microspectroscopy is a method that can be used to extract
finer spatial and spectral details from biological tissue samples [28]. In SR-FTIR, a synchrotron source
emits a collimated light beam more intense than standard bench-top spectrometers [41,42]. Synchrotron
radiation can be up to 103 times brighter than any other conventional broadband IR source, allowing
smaller regions of tissue to be probed with superior signal-to-noise [43]. Thus, SR-FTIR spectroscopy
offers a high-resolution approach that can be valuable for proof-of-principle studies in acquiring greater
biological information.
The implementation of FTIR spectroscopy during surgical biopsy could present a fast, label-free
method for the molecular genetic classification of gliomas. IDH1 mutation is associated with a
better prognosis, as is maximal surgical resection [44]. Attempted maximum safe surgical resection
may be more justified in patients with IDH1-mutant gliomas, whilst a more limited resection may
be more appropriate for IDH1-wildtype gliomas. Intra-operative rapid determination of tumour
IDH1 status could therefore inform neurosurgical decision-making [45]. In this study, SR-FTIR has
been used to examine human brain glioma tissue, where single-point spectra have been collected
from tissue microarray (TMA) sections comprising IDH1-mutated and IDH1-wildtype glioma tissue
cores. Additionally, we examine the potential for earlier molecular subclassification of tumours by
identifying the biomolecular alterations caused by the genetic IDH1 mutation in glioma patient serum.
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The combination of centrifugal filtration and ATR-FTIR serum spectroscopy could be implemented
prior to biopsy or resection to determine IDH1 status even before surgery.
2. Materials and Methods
2.1. Sample Collection
2.1.1. Glioma Tissue
Formalin-fixed paraffin-embedded (FFPE) tumour tissue was obtained from patients who
underwent neurosurgery (e.g., tumour biopsy or debulking) with a histologically confirmed glioma as
diagnosed by a consultant neuropathologist. In total, 137 patients were selected for inclusion in the
TMA from an institutional database of all surgical neuro-oncology patients, in order to represent a
range of tumour grades and histological subtypes, as well as matched samples from recurrent tumours.
Anonymised clinical information was available. Ethical approval for the construction of the TMA
was from the Lothian NRS Bioresource (15 ES 0094). The microarray was constructed from 0.6 mm
diameter cores of the FFPE tissue, which were inserted into a recipient block using a manual tissue
arrayer. Sections of the TMA block 10 µm thick were sliced with a microtome and floated onto three
76 × 26 × 1 mm calcium fluoride (CaF2) substrates in a heated water bath (~40 ◦C). The CaF2 slides
were placed into an automated Leica ST5010 Autostainer XL (Leica, Wetzlar, Germany) for a dewaxing
protocol, designed to remove the paraffin wax before spectroscopic analysis, which proceeded as
follows: immersion in xylene (3 × 5 min), ethanol wash (2 × 2 min 100%, 1 × 2 min 80%, 1 × 2 min 50%),
rinse in distilled water (2 × 2 min). The dewaxed slides were placed into an oven at 60 ◦C for 3 h to dry
the samples efficiently onto the CaF2 substrates. The quantity of each tissue core within the TMA block
varied, and thus a small portion of the patients could not be sampled. Once dehydrated, the slides
were stored in petri dishes at room temperature until the time of IR interrogation. IHC staining of
the tissue cores was separately performed on 4 µm slices using the mIDH1R132H antibody. Reference
microscope images were collected, allowing the characterisation of the IDH1-status of each sample; a
positive result is indicated by a strong brown colour in the glioma cells (Figure 1).
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Figure 1. Overview of the tissue microarray with IDH1 staining, with focus on a mutated core (brown)
and wildtype core (blue).
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2.1.2. Patient Serum
In total, 72 serum samples were obtained from the Walton Centre NHS Trust biobank
(Liverpool, UK) from patients with a pathologically confirmed glioma, prior to receiving any
chemotherapy or radiotherapy. Ethical approval was obtained (Walton Research Bank and
BTNW/WRTB 13_01/BTNW Application #1108). Blood samples had been gathered in serum collection
tubes and allowed to clot for up to one hour. The tubes had then been centrifuged for 15 min at 2200×
g. The serum component was subsequently aliquoted then stored in a −80 ◦C freezer until the time
of analysis.
Centrifugal Filtration
To assess whether ATR-FTIR spectroscopy could detect IDH1 mutation, centrifugal filtration was
undertaken to enable analysis of the low molecular weight (LMW) fraction of the serum samples.
The whole serum from the 72 brain cancer patients (Table S1) was filtered to remove the more abundant
high molecular weight (HMW) biomolecules. Commercially available Amicon Ultra 0.5 mL centrifugal
filtering devices (Millipore-Merck, Darmstadt, Germany) with cut-off points at 3 kDa were used to
fractionate the serum samples. The serum was split into two fractions: the ‘filtrate’ and the ‘concentrate’.
The filtrate accounts for the biomolecular components below the 3 kDa cut-off point, and the concentrate
represents the higher molecular weight serum constituents. Serum from each patient (0.3 mL) was
placed in the centrifugal filters, and the filtration tubes were centrifuged for 30 min at a speed of
14,000× g. The filtrates passed through the membranes into the collection vials. The filters were then
inverted and centrifuged for 2 min at 1000× g to collect the HMW concentrates. The filtrates and
concentrates were stored in a −80 ◦C freezer until the time of analysis.
2.2. Spectral Collection and Data Analysis
2.2.1. Synchrotron Radiation-Based FTIR Microspectroscopy
Experiments were carried out at the Diamond Light Source synchrotron facility, UK, namely
on the Multimode Infrared Imaging and Microspectroscopy (MIRIAM) B22 beamline [46,47].
FTIR microspectra were acquired in transmission mode via a Hyperion 3000 microscope system
with a 36×magnification (NA = 0.5) Cassegrain objective/condenser optics coupled to a Bruker Vertex
80v FTIR spectrometer (Bruker Optics, Ettlingen, Germany). A high sensitivity liquid nitrogen cooled
mercury cadmium telluride (MCT) single element detector with a 50 mm pitch size was used to collect
data between 4000 and 600 cm−1, at a spectral resolution of 4 cm−1. Background spectra were recorded
from clean sections on the CaF2 substrates. The aperture size was set to have a projected detection
area of 10 × 10 µm on the sample plane, with FTIR spectral acquisition performed by co-addition of
256 background scans and 128 sample scans at an FTIR nominal scanner rate of 80 kHz (equivalent
to 10 s and 20 s per point, respectively). Point spectra were collected as linescans through diagonal
cross-sections of the TMA cores, acquiring approximately ~70 spectra for each TMA core across a
line approximately 0.6 mm in length (this ranged from around 40–80 spectra depending on the size
and quality of each core). In total, 8532 spectra were accumulated from 99 TMA cores from two CaF2
slides of consecutive tissue sections (Table S2), comprised of tumour tissue from 79 glioma patients.
Each transmission spectrum was ratioed to the background spectrum and converted to absorbance.
An initial atmospheric compensation was performed to subtract the contribution of spectral water
vapour bands in OPUS 8 software (Bruker Optics, Ettlingen, Germany), and the resulting spectra
were cut to 4000–900 cm−1. The spectral data was exported for further pre-processing and analysis.
Absorbance spectra collected from clean sections of the CaF2 substrates were subtracted from sample
absorbance spectra. The PRFFECT toolbox on the R Statistical Computing Environment was utilised
for the pre-processing and classifications [16]. Iterative extended multiplicative signal correction
(EMSC) was applied five times with five different reference spectra to account for Mie scattering [48].
Principal component analysis (PCA) was employed on Quasar software (Orange Data Mining [49]) for
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a PCA-based quality test, to remove spectra that fell outside the central cluster of PC scores. Thereafter,
spectra with Amide I (1650 cm−1) absorbance <0.01 or >2 were removed from the dataset, as where the
absorbance is <0.01 the spectral sensitivity decreases by two orders of magnitude, whereas above >2
the linearity of the detection is compromised, e.g., the stronger signal of typically Amide I cannot be
ratioed properly to the other IR bands. The synchrotron datasets were classified based on IDH1 status
using linear discriminant analysis (LDA). LDA is a dimensionality reduction technique which can
work as a linear classifier, and it focuses on maximising the separability among the known categories.
LDA classifiers make predictions by estimating the probability that a new set of inputs belong to each
category, and the class that gets the highest probability is predicted as the output class [50]. Firstly,
a grid search was utilised to test various pre-processing parameters, then the top 10 models were further
examined with a greater number of iterations. More information on the grid search and the iterations
process is contained in the results section. Model performance is reported in terms of sensitivity and
specificity. These values are calculated based on the number of correct and incorrect predictions in the
external test set; the sensitivity refers to the ability to correctly identify the IDH1-mutated samples,
whereas the specificity is the ability to successfully pick out the IDH1-wildtype patients. We direct the
reader to our previous work for more information on the statistical analysis employed here [51].
2.2.2. ATR-FTIR Spectroscopy
The frozen serum samples were thawed at room temperature prior to spectral analysis. Then,
3 µL deposits were pipetted onto each of the three sample wells on a ClinSpec Dx optical sample slide
for spectroscopic analysis (ClinSpec Diagnostics Ltd., Glasgow, UK) [52]. The first well remained clean
for a background measurement, in order to account for atmospheric conditions [53]. The serum drops
were dehydrated in a drying unit incubator (Thermo Fisher Scientific, Massachusetts, USA) at 35 ◦C
for 1 h [53–55].
A Perkin Elmer Spectrum 2 FTIR spectrometer (Perkin Elmer, London, UK) coupled with a
ClinSpec Dx indexer accessory (ClinSpec Diagnostics Ltd., Glasgow, UK) was used for the spectral
collection. The spectra were acquired in the range 4000–450 cm−1, at a resolution of 4 cm−1, with
1 cm−1 data spacing and 16 co-added scans. Each sample well was analysed in triplicate, acquiring 9
spectra per patient. Thus, we gathered 648 whole serum spectra, and 648 spectra were collected from
the <3 kDa filtrates, resulting in 1296 spectra in total.
An EMSC was also employed for the serum data analysis. The ‘whole serum’ dataset used a human
pooled serum reference, followed by a spectral cut to 1800–1000 cm−1. To develop the classification
models, patients were randomly split into training and test sets at a 70:30 split. Spectra from a single
patient’s serum could only appear in one cross-validation fold, and in either the training or test set.
The majority vote amongst the nine spectra for each patient was reported as either IDH1-mutated or
IDH1-wildtype. The classification models were retrained and tested on 100 different randomly selected
training and test set partitions to provide a more reliable result. Classification results of the ATR-FTIR
spectra from random forest (RF), partial least squares–discriminant analysis (PLS-DA), and support
vector machine (SVM) analysis have been compared here, as described in our previous work [51,56].
Centrifugal Filtration
For the centrifugal filtration study, the spectra were initially corrected with EMSC using an
averaged filtrate spectrum as the reference. Since there were two prominent bands present between
1000 and 800 cm−1 in the filtered serum spectrum, the dataset was cut down to 800 cm−1 to ensure
all potentially important biological information was retained. Thus, three spectral cuts were tested:
4000–800 cm−1, 1800–800 cm−1 and 1800–1000 cm−1. All other parameters were consistent with the
whole serum analysis.
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3. Results
3.1. Synchrotron Microanalysis
We collected large images containing multiple tissue cores, then accumulated single-point spectra
as linescans across each individual core. Of the 8532 spectra that were collected, some were not
representative of the tissue samples, as certain areas of the diagonal cross-sections contained blank
CaF2, mainly at the sample’s edge (Figure 2). The spectra of the blank substrate were removed from
the dataset. As shown in Figure 3, the raw spectra collected from the tissue samples were highly
variable. The signal variation towards 1000 cm−1 can be related to the optical diffraction limit when
using slits comparable to the wavelength, plus a dispersive effect due to the CaF2 substrate. It is
well established that the transmission IR microscopy of tissue samples can suffer from significant
baseline distortions from the basic offset, due to local optical density, predominantly resonant Mie
scattering [57]. To combat this, an iterative EMSC approach was employed, as described elsewhere [48].
The resulting spectra were subjected to a PCA-quality test, described in Figure 4 (initial PCA plot
can be found in Figure S1). All datapoints positioned outside of the centroid ellipse relate to spectra
that had a significant scatter (gathered from rough sections of the TMA cores, e.g., the edges of the
samples, or where no sample was present) and were removed from subsequent analysis. Additional
quality testing was based on the intensity of the Amide I band, with only the spectra falling within an
acceptance window of 0.01–2 being retained. The resulting spectra are outlined in Figure 5, where the
baseline variation and scattering effects have been significantly reduced.
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Following the data management described, 4822 spectra were retained for further spectral
pre-processing and classification. In order to determine the optimal pre-processing parameters for
the IDH1-mutated versus IDH1-wildtype dataset, a grid se rch was c rried ut sing the PRFFECT
to lbox, where the values for normalisation, binn g, smoothing, order of der vative, nd spectral cut
were altered, as outlined in Table 2. A spectral cut of 1800–1200 cm−1 was included as t ere appeared
to be a drop in sign below <1200 cm−1 for many sa ples, which was thought to be a result of the
loss of IR light transmittance through the C F2 slides (Figure S2). Thu , the fingerprint region with
the removal of wavenumbers <1200 cm−1 w s included in t e grid earch, along with the typical
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biological fingerprint region (1800–1000 cm−1) and the full spectral region. In total, 576 combinations
of pre-processing parameters were tested.
Table 2. Pre-processing parameters examined in machine learning grid search.
Parameter Variations
Normalisation (n) None (0) Min-max (1) Vector (2) Amide I (3)
Derivative (l) None (0) First (1) Second (2) -
Binning (b) 1 2 4 8
Smoothing with Savitzky–Golay filter (s) None (0) 2 3 4
Spectral cut (p) None (0) 1800–1000 cm−1 1800–1200 cm−1 -
The processed datasets were split 70:30 into training and testing sets. An LDA classifier was
trained and predictions made on the testing set, resampled 11 times (i.e., repeated for 11 different
train–test splits), and the classification probability threshold was chosen to optimise Cohen’s Kappa
(κ). Briefly, the values of κ range from below zero to one, and measure the level of agreement between
the classifier and the pathology, with higher values representing better agreement, thus signifying a
more reliable diagnostic model [58]. The models predicted IDH1 status on a ‘by sample’ basis, where
the majority vote for each tissue core was reported as either IDH1-mutated or IDH1-wildtype. Here,
the sensitivity is the ability to detect the positive class (the IDH1 mutation), and specificity refers
to IDH1-wildtype predictions. The results from all 11 iterations were averaged and compiled for
comparison (Table S3).
The best performing model from the grid search reported a k value of 0.65, which demonstrates a
substantial level of agreement [59]. This model provided a sensitivity and specificity of 87.8% and
86.2%, respectively, and the employed pre-processing was a min–max normalisation (i.e., scaling
spectrum to between 0 and 1), followed by a binning factor of 4, a Savitzky–Golay (SG) filter with
a filter length 7 and filter order 4, and a spectral cut to between 1800 and 1200 cm−1. The resulting
mean spectra for both the IDH1-mutated and IDH1-wildtype patient groups are outlined in Figure 6.
By plotting the difference between these mean spectra, it becomes evident that there are dissimilarities
between the two IDH1 groups (Figure 7).
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Figure 7. Difference spectrum of mean IDH1-mutated and IDH1-wildtype absorbance spectra for the
synchrotron-based IDH1 dataset, with tentative biological assignments and associat d vibrati nal
modes: ν = stretching; δ = bending; γ = wagging, twisting and rocking; as = asymmetri ; s = symmetric.
A reliable classification result was anticipated since 11 resamples were employed in the grid
search with different randomly selected training and test sets each ti e, and since the model reported
a substantial level of agree ent (k = 0.65). To ensure these findings were consistent, the top
10 pre-processing parameters from the grid search were further examined. Additionally, sampling
techniques were utilised to combat the class imbalance between mutated and wildtype samples,
ensuring no bias was present within the models. Each of the retained pre-processing combinations
were classified by LDA with 51 resamples, and four sampling methods were tested in each instance:
no additional sampling, up- and down-sampling, and synthetic minority over-sampling technique
(SMOTE), based on our previous work [51]. The optimal pre-processing parameters from the initial
grid search were also found to be the best in this case, when combined with additional up-sampling
(Table S4). The diagnostic ability decreased slightly, wit a reported 82.4% sensitivity and 83.4%
specificity (Table 3). The standard deviation is much higher for the sensitivity than the specificity, as is
further defined by the confusion matrices in Figure S3.
Table 3. Classification results from 51 resamples of the optimal LDA model with additional up-sampling,
in terms of sensitivity, specificity and balanced accuracy.
Statistic Mean Standard Deviation
Sensitivity (%) 82.4 16.8
Specificity (%) 83.4 8.2
Balanced Accuracy (%) 82.9 9.6
Receiver operating characteristic (ROC) curves can also demonstrate a model’s diagnostic ability.
Figure 8 describes a mean curve obtained from a resampled LDA ‘by sample’ classifier between
IDH1-mutated and IDH1-wildtype. The curve is symmetrical across sensitivity and specificity, and
reports an area under the curve (AUC) value of 0.8994, which is typically considered an excellent
degree of discrimination between two classes [60]. By altering the probability threshold, denoted ‘p’ in
Figure 8, we can maximise the sensitivity (A) or specificity (B), or obtain the greatest balance between
the two (C). Point A represents the highest sensitivity (90%) whilst remaining in the 70% target region,
whereas B denotes the maximum specificity (91%). The most balanced point on the curve used a
probability threshold of 0.28 for every resample, and reported a sensitivity and specificity of 82% and
Cancers 2020, 12, 3682 11 of 22
81%, respectively. This corroborates the high diagnostic ability of the model, and signifies some real
promise for the determination of IDH1 status through SR-FTIR microspectroscopy.
Cancers 2020, 12, x 11 of 22 
 
specificity of 82% and 81%, respectively. This corroborates the high diagnostic ability of the model, 
and signifies some real promise for the determination of IDH1 status through SR-FTIR 
microspectroscopy. 
 
Figure 8. Mean receiver operator characteristic (ROC) curve displaying the trade-off between 
sensitivity and specificity for 51 resampled linear discriminant analysis (LDA) classifiers. The grey 
square is a target region of at least 70% for both sensitivity and specificity. The ‘x’ labels are the points 
on the curve that maximise sensitivity (A), specificity (B) and balance the two (C) whilst remaining in 
the target area, and ‘p’ represents the probability thresholds at those points on the curve. 
3.2. ATR-FTIR Results 
Brain cancer patients, with either astrocytoma, oligodendroglioma or GBM, were separated 
based upon their IDH1 status using ATR-FTIR serum spectroscopy. Of the 72 patients included, there 
were 36 with the IDH1 mutation and 36 IDH1-wildtype. The data were classified through RF, PLS-
DA and SVM with 100 resamples for each, and the findings are reported in Table 4 on a ‘by patient’ 
basis. For the whole serum dataset, the sensitivities were much higher than the specificities in each 
case. For example, the SVM model reported a promising sensitivity of 75.9%, but had an extremely 
low specificity of 28%. 
  
1.0 0.8 0.6 0.4 0.2 0.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
M ean S ensitivity S pecificity curve
A U C  = 0.8994
Specificity
Se
ns
iti
vi
ty
x
A
x
B x
C
A
B
C
Spec: 70%
Sens: 90%
p = 0.16
Spec: 91%
Sens: 70%
p = 0.47
Spec: 82%
Sens: 81%
p = 0.28
A
B
C
Spec: 70%
Sens: 90%
p = 0.16
Spec: 91%
Sens: 70%
p = 0.47
Spec: 82%
Sens: 81%
p = 0.28
Figure 8. Mean receiver operator characteristic (ROC) curve displaying the trade-off between sensitivity
and specificity for 51 resampled linear discriminant analysis (LDA) classifiers. The grey square is a
target region of at least 70% for both sensitivity and specificity. The ‘x’ labels are the points on the curve
that maximise sensitivity (A), specificity (B) and balance the two (C) whilst remaining in the target area,
and ‘p’ represents the probability thresholds at those points on the curve.
3.2. ATR-FTIR Results
Brain cancer patients, with either astrocytoma, oligodendroglioma or GBM, were separated based
upon their IDH1 status using ATR-FTIR serum spectroscopy. Of the 72 patients included, there were 36
with the IDH1 mutation and 36 IDH1-wildtype. The data were classified through RF, PLS-DA and SVM
with 100 resamples for each, and the findings are reported in Table 4 on a ‘by patient’ basis. For the
whole serum dataset, the sensitivities were much higher than the specificities in each case. For example,
the SVM model reported a promising sensitivity of 75.9%, but had an extremely low specificity of 28%.
Table 4. Classification results for the IDH1-mutated versus IDH1-wildtype whole serum dataset,
after 100 resamples. The mean sensitivity, specificity and balanced accuracy are reported with their
corresponding standard deviations (SD).
Sample Fraction Model
Sensitivity (%) Specificity (%) Balanced Accuracy (%)
Mean SD Mean SD Mean SD
Whole Serum
RF 50.3 15.2 45.4 15.1 47.9 8.6
PLS-DA 69.3 13.8 35.3 14.7 52.3 7.4
SVM 75.9 17.5 28.0 14.6 51.9 7.7
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Figure 9 provides an example of the IR spectra for whole serum, the >3 kDa ‘HMW’ fraction and
the <3 kDa ‘LMW’ fraction. The concentrate appears almost identical to the whole serum spectrum;
notably, they have a very similar absorbance to the more abundant proteins that exist within the
Amide region, such as albumin and immunoglobulins. With these large proteins and other HMW
constituents removed, the filtrate spectrum looks remarkably different, with only a few distinct peaks
in the fingerprint region (<3 kDa, top spectrum). Three spectral regions were chosen for examination:
4000–800 cm−1 and 1800–800 cm−1, to encompass the two distinct peaks around 950 cm−1 and 850 cm−1,
as well as the typical biological fingerprint region (1800–1000 cm−1). The classification results are
reported in Table 5.
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Table 5. Classification results for the IDH1-mutated versus IDH1-wildtype serum datasets after 100
resamples. The mean sensitivity, specificity and balanced accuracy are reported with their corresponding
standard deviations (SD). The best performing model for each sample fraction is highlighted in bold.
Sample Fraction Model
Sensitivity (%) Specificity ( ) Balanced Accuracy (%)
Mean SD Mean SD Mean SD
<3kDa Filtered Serum (4000–800 cm−1)
RF 68.4 16.2 67.5 15.9 68.0 11.1
PLS-DA 75.5 12.3 62.6 15.5 69.1 9.0
SVM 68.4 16.5 64.2 16.0 66.4 10.2
<3kDa Filtered Serum (1800–800 cm−1)
RF 70.6 17.8 66.4 14.5 68.5 11.2
PLS-DA 65.0 14.6 64.6 16.5 64.8 8.7
SVM 63.2 16.3 63.8 16.9 63.5 9.6
<3kDa Filtered Serum (1800–1000 cm−1)
RF 66.6 15.4 68.1 14.1 67.4 9.9
PLS-DA 65.9 14.6 56.2 15.5 61.1 9.1
SVM 68.1 15.6 56.8 15.6 62.5 10.1
Bold: the best performing models.
In each case, the filtrate models were superior to the whole serum models in successfully detecting
the IDH1-wildtype patients, reporting specificity values above 60%. The improvement in diagnostic
ability due to the filtration step is emphasised in Figure 10, which displays single model ROC curves
for the three whole serum classifiers (Figure 10a) and the best models for each of the three filtrate
datasets (Figure 10b). As expected from the poor classification results, the ROC curves for the whole
serum models fall on the diagonal line, meaning the predictions that are being made are no better than
random guesses, and the reported AUC values of ~0.5 suggest the test has essentially no diagnostic
accuracy [61]. However, the inclusion of centrifugal filtration enhanced the ability to successfully
Cancers 2020, 12, 3682 13 of 22
discriminate the two IDH1 classes. The corresponding ROC curves in Figure 10b report AUC values
>0.7, which is often deemed an acceptable level of discrimination [60].
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Figure 10. Single model receiver operator characteristic (ROC) graphs for the (a) whole serum dataset
displaying the PLS-DA (blue), SVM (red) and RF (green) classifiers; and (b) the best performing model
for each of the tested filtrate fractions: the full spectrum (4000–800 cm−1, blue), the fingerprint region
(1800–1000 cm−1, red) and the extended fingerprint region (1800–800 cm−1, green).
The <3 kDa filtered serum ‘full spectra’ dataset (4000–800 cm−1) delivered the greatest balanced
accuracy of 69.1% when classified by the PLS-DA model. The PLS scores plot in Figure 11a describes
the general variation within the dataset. The major variance is generally described by the first PLS
component (PLS1). The PLS1 loadings suggest large differences of ~3400 cm−1 and ~1650 cm−1
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(Figure S4), although there is no apparent class separation across PLS1 in the scores plot. Despite
some overlap, it is evident that the second PLS component (PLS2) separates the two classes better
than PLS1. The PLS2 loadings also highlight significant spectral differences around ~1650 cm−1
(Figure 11b). Interestingly, this is the typical location of the large Amide I band in a normal serum
spectrum, accounting for the bond vibrations within an abundance of protein molecules. Even with
the HMW proteins filtered out of the samples, such as albumin and immunoglobulins, it still appears
to be a region of importance when examining molecules of very low molecular weights (<3 kDa),
suggesting the smaller protein molecules still have diagnostic potential. Considerable contributions
from lipids (~1450 cm−1), nucleic material (~1100 cm−1) and C-O-C stretching vibrations associated
with carbohydrates and glycogen were apparent in the PLS2 loadings, as well as other proteinaceous
vibrations (~1550 cm−1 and ~1300 cm−1).
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Figure 11. (a) the PLS scores plot between PLS1 and PLS2 for the IDH1-mutated (black) and
IDH1-wildtype (red) data from the <3 kDa serum filtrate (4000–800 cm−1) dataset, and (b) the
loadings for the 2nd PLS component.
The RF model for the 1800–800 cm−1 dataset also reported promising results, with a sensitivity
and specificity of 70.6% and 66.4%, respectively. The Gini impurity etric was examined to identify the
most important features within each dataset (Figure S5) [62]. Table 6 gives an overview of the top 15
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identified wavenumbers in order of importance, with their corresponding wavenumber assignments
and vibrational modes [27]. The top wavenumbers mostly account for the stretching vibrations of
C-O, C-C and C-OH bonds, which are often associated with carbohydrates, glycogen and nucleic
acids. Additionally, the symmetric PO−2 stretching vibrations from DNA and CH2 twisting and
bending vibrations associated with lipids were deemed significant in the RF classification. Likewise,
wavenumbers in the Amide region were considered important here, accounting for C = O/C-N
stretching and N-H bending vibrations in the amide bonds within protein molecules, similar to the
PLS loadings described in Figure 11.
Table 6. The top 15 wavenumbers from the <3 kDa serum filtrate (1800–800 cm−1) random forest
classification between IDH1-mutated and IDH1-wildtype with associated vibrational modes [27]. The
column “ΣGini” is a summation of the mean decrease in Gini for each wavenumber, over all nodes in
all trees in the random forest ensemble, which suggests the regions of highest importance.
Wavenumbers (cm−1)
∑
Gini Vibrational Modes
1124.5 12.31 C-O stretch
1172.5 11.22 C-O, C-OH stretch
1164.5 9.07 C-C, C-O and C-OH stretch
1180.5 6.43 CH2 twisting
1116.5 5.39 RNA; C-OH stretch
1028.5 5.01 Carbohydrate; C-O stretch
1188.5 4.46 DNA; Symmetric PO−2 stretch
1740.5 4.19 Lipids; C = O stretch
1020.5 3.60 Glycogen; C-O stretch
1132.5 3.49 C-O and C-C stretch
1588.5 2.77 Amide I; C = O and C-N stretch, N-H bending
1548.5 2.73 Amide II; N-H bending, C-N stretching
1444.5 2.57 Lipids; CH2 bending
1468.5 2.52 Lipids/Proteins; CH2 bending
1612.5 2.45 Amide I; C = O and C-N stretch, N-H bending
4. Discussion
In the synchrotron data analysis, a spectral cut of 1800–1200 cm−1 was included in the initial grid
search as there appeared to be a drop in signal below <1200 cm−1. This cut-off effect for CaF2 in the low
wavenumber region is common in scanning microscopy and can be caused by the change in refractive
index (RI), e.g., the RI of CaF2 decreases from ~1.4 at 5 µm to ~1.3 at 10 µm. Additionally, when using
a synchrotron source in the scanning microscopy mode for high spatial resolution, the diffraction limit
is achieved when the microscope’s aperture defines a spot size scaled with the longest wavelength of
the spectral region of interest [63]. Here, we used 10 µm slits, and therefore the diffraction limit could
be affecting the signal towards 1000 cm−1 (full width half maximum (fwhm) ~l/2*NA = l = 10 µm,
i.e., same size as the slit size used for scanning microspectroscopy) [64]. This did not appear to be a
significant problem as the optimal pre-processing method involved the removal of this spectral region.
In Figure 7, arguably the largest difference between the IDH1-mutated and IDH1-wildtype groups
arises within the Amide I band, associated with the stretching of double-bonded carbonyl groups
(C = O) and C-N bonds, as well as N-H bending vibrations in proteinaceous biomolecules [27].
The lower-wavenumber side of the Amide I band (1620–1600 cm−1) was more intense in the
IDH1-mutated spectra (positive regions in the difference spectrum), whereas the band intensities
between 1700 and 1650 cm−1 were lower compared to the IDH1-wildtype tissue spectra. This is
consistent with a study wherein IDH1-mutated cell lines exhibited an elevated absorbance at 1610 cm−1,
but a lower intensity around 1690 cm−1 [40]. These findings are not directly comparable to the results
presented here, as cell lines may not adequately represent primary cells in clinical specimens [65].
The observed differences are likely to result from alterations in overlapping bands existing within
the broad Amide I envelope, accounting for various protein secondary structures that can only be
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revealed with deconvolution techniques [66]. It is thought that the large negative peak in the difference
spectrum at ~1660 cm−1 may represent a deviation in the levels of α-helical structures, and the smaller
positive peak ~1615 cm−1 may be tentatively assigned to β-sheet components [67]. The band intensities
at approximately ~1750 cm−1 and ~1560 cm−1 were lower in the mean IDH1-mutated spectrum,
while those at ~1495 cm−1 and between 1450 and 1200 cm−1 displayed a higher absorbance than the
IDH1-wildtype spectra (Figure 7).
Several spectral differences are similar to previous findings, namely, the variances in Amide
III of proteins (mainly N-H in plane bending and C-N stretch, ~1300 cm−1), nucleic material such
as DNA and RNA (PO−2 asymmetric stretch, ~1230 cm
−1), and lipidic contributions (C = O stretch,
~1750 cm−1; CH3 bending, ~1450 cm−1) [40]. The disparities in the IR spectra could potentially be
attributed to the increase in 2HG in the IDH1-mutated glioma tissue, which is known to be elevated in
tumour cells with the IDH1 mutation [8]. With reference to an IR spectrum of pure 2HG [40], the bands
around 1589, 1450, 1416, 1344, 1311, 1267, 1236 and 1203 cm−1 could explain some of the differences
observed between IDH1-mutated and IDH1-wildtype tissue in this study, as the band intensities at
these wavenumbers are all elevated in IDH1-mutated patients, as described by the difference spectrum
(Figure 7). That being said, it may only indicate a global change in biomolecular content, reflected by
the systemic response of the genetic mutation within the glial tumour cells.
The disparities in the classification results between the initial grid search and the LDA model
resampled 51 times highlight the importance of utilising a reasonable number of iterations, in order to
minimise the variance whilst maintaining a respectable analysis time. However, the sensitivity and
specificity remained well-balanced and above 80%, which are highly promising results. As shown
in Table 3, the standard deviation is much higher for the sensitivity than the specificity, which is
not entirely surprising because of the lower number of IDH1-mutated samples within the dataset.
A 70:30 split between training and testing data meant that there were only seven randomly selected
IDH1-mutated samples in each of the 51 resampled test sets. Therefore, when a known mutated tissue
core is misdiagnosed as IDH1-wildtype, it has a substantial effect on the sensitivity. As described in the
confusion matrices in Figure S3, there is a drop of ~15% in sensitivity when an IDH1-mutated sample
is predicted wrongly. Conversely, there is only a ~4% difference in specificity with a misdiagnosed
IDH1-wildtype, as there were 26 IDH1-wildtype samples in every test set. Thus, the addition of more
glioma samples with the IDH1 mutation would be beneficial for this analysis, in order to minimise the
associated error. Nevertheless, these values demonstrate significant potential, and a mean balanced
accuracy of 82.9% indicates synchrotron-based transmission FTIR is capable of identifying mutated
and wildtype IDH1 tumours.
Regarding the ATR-FTIR results, the whole serum classifiers seemed to be more effective at
predicting the IDH1-mutated serum samples from the test sets, as the sensitivities were much higher
than the specificities in each case. It is not clear why this may be, as there were an equal number of
samples in each class, and therefore there should be no bias present in the models. That being said,
the results did not appear to be reliable, and given the poor balanced accuracies (~50%), it could
be assumed that the correct predictions were ultimately made by chance. Likewise, the low AUC
values from the ROC curves (Figure 10) suggest they had no diagnostic ability. The LMW fraction
of the serum is believed to contain disease-specific information, making the spectroscopic signature
of this fraction useful for diagnostics [68]. Thus, after the poor classification performance for the
whole serum data, it was thought that discrete molecular differences could potentially be emphasised
through the use of centrifugal filtration. The balanced accuracies were enhanced to between 60 and
70% for all tested filtrate models. The centrifugal filtration step produced a significant improvement
in the model’s performance, by delivering more balanced sensitivities and specificities. Similar to
the tissue-based results, these findings are based on a relatively small cohort with only 36 patients in
each class, thus misdiagnosed patients have a profound effect on the sensitivity or specificity values.
Additional analysis with a larger patient cohort would be beneficial in identifying the true potential of
the technique for this particular clinical application.
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5. Limitations
Despite the promising results reported in this preliminary study, it is important to highlight some
of the limitations. Since we have utilised the UK’s synchrotron facility here, the current methodology is
not directly translatable to the hospital setting. Synchrotron instruments are admirable for high spatial
resolution; thus, it was chosen in this project to attain the greatest level of biological and diagnostic
detail from the glioma samples. Synchrotron measurements can be subject to lengthy analysis times,
but standard bench-top FTIR spectrometers can acquire similar data quality with more efficient analysis.
The ability to discriminate the IDH1 mutation in glioma TMA sections with 80% accuracy would likely
be clinically acceptable, although future studies should also consider probing fresh tissue biopsies
rather than FFPE tissue microarrays, which would be better suited to the determination of a patient’s
IDH1 status mid-surgery.
The whole serum results reported an accuracy of ~50%, which would not be deemed acceptable
in the clinic. Blood serum comprises thousands of different proteins, ranging from the more abundant
HMW serum albumin (50 g/L) to the LMW proteins like troponin (1 ng/L) [69]. Due to the wealth of
various biomolecules that exist in a normal serum sample, it was expected to be a significant challenge
to identify the subtle alterations in blood composition that may have been associated with the IDH1
mutation. The filtration step did improve the classification performance, increasing the accuracy up to
almost 70%. Although, it has been suggested elsewhere that the large absorbance band observed in the
filtered serum spectrum (Figure 9, ~1030 cm−1) is due to glycerine interference, introduced into the
sample from the centrifugal filters [70]. This could potentially be obscuring crucial information that
may help improve the test performance. Future research could implement a washing step prior to
centrifugation. There are also many filter sizes to choose from, hence filtration with a different cut-off
point may also further improve classification performance. Many cytokines and chemokines exist at
molecular weights greater than 3kDa, which may be indicative of disease.
As already stated, both the tissue and serum analysis could benefit through the addition of more
patients, preferably from prospective trials, which would likely reduce the standard error within the
classification models. It is vital that more efficient methods are developed for this application before
clinical translation can be realised.
6. Conclusions
FTIR spectroscopy during surgical tissue biopsy as a label-free test for the molecular genetic
classification of gliomas could impact on surgical decision-making, in particular about the extent of
resection. The initial synchrotron-based microanalysis reported 87.8% sensitivity and 86.2% specificity.
Further examination utilising a higher number of resamples slightly reduced the diagnostic outcome,
with 51 LDA iterations reporting a balanced accuracy of 82.9%. ROC analysis produced a mean curve
with an AUC of 0.8994, which also suggests a good degree of diagnostic separability. This demonstrates
significant potential for detecting the molecular alterations initiated by genetic mutations in the
IDH1 enzyme.
Identification of the molecular status from blood serum prior to biopsy could further direct
some patients to alternative treatment strategies. Initially, the whole serum classifiers performed
poorly, delivering balanced accuracies of ~50%. Yet with the introduction of centrifugal filtration,
the classification performance improved significantly, enhancing the sensitivities and specificities to
around 70%. These strategies can now be validated and optimised in prospective clinical studies, and
can be extended to identify other important molecular alterations, such as ATRX loss, 1p/19q co-deletion
and/or MGMT hypermethylation, with which brain cancer type can be stratified pre-operatively.
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21. Bird, B.; Miljković, M.; Remiszewski, S.; Akalin, A.; Kon, M.; Diem, M. Infrared spectral histopathology
(SHP): A novel diagnostic tool for the accurate classification of lung cancer. Lab. Investig. 2012, 92, 1358.
[CrossRef]
22. Lasch, P.; Haensch, W.; Naumann, D.; Diem, M. Imaging of colorectal adenocarcinoma using FT-IR
microspectroscopy and cluster analysis. Biochim. Biophys. Acta BBA Mol. Basis Dis. 2004, 1688, 176–186.
[CrossRef]
23. Theophilou, G.; Lima, K.M.G.; Martin-Hirsch, P.L.; Stringfellow, H.F.; Martin, F.L. ATR-FTIR spectroscopy
coupled with chemometric analysis discriminates normal, borderline and malignant ovarian tissue:
Classifying subtypes of human cancer. Analyst 2016, 141, 585–594. [CrossRef] [PubMed]
24. Gazi, E.; Baker, M.; Dwyer, J.; Lockyer, N.P.; Gardner, P.; Shanks, J.H.; Reeve, R.S.; Hart, C.A.; Clarke, N.W.;
Brown, M.D. A Correlation of FTIR Spectra Derived from Prostate Cancer Biopsies with Gleason Grade and
Tumour Stage. Eur. Urol. 2006, 50, 750–761. [CrossRef] [PubMed]
25. Baker, M.J.; Gazi, E.; Brown, M.D.; Shanks, J.H.; Gardner, P.; Clarke, N.W. FTIR-based spectroscopic analysis
in the identification of clinically aggressive prostate cancer. Br. J. Cancer 2008, 99, 1859–1866. [CrossRef]
26. Baker, M.J.; Gazi, E.; Brown, M.D.; Shanks, J.H.; Clarke, N.W.; Gardner, P. Investigating FTIR based
histopathology for the diagnosis of prostate cancer. J. Biophotonics 2009, 2, 104–113. [CrossRef] [PubMed]
27. Movasaghi, Z.; Rehman, S.; ur Rehman, D.I. Fourier Transform Infrared (FTIR) Spectroscopy of Biological
Tissues. Appl. Spectrosc. Rev. 2008, 43, 134–179. [CrossRef]
28. Baker, M.J.; Trevisan, J.; Bassan, P.; Bhargava, R.; Butler, H.J.; Dorling, K.M.; Fielden, P.R.; Fogarty, S.W.;
Fullwood, N.J.; Heys, K.A.; et al. Using Fourier transform IR spectroscopy to analyze biological materials.
Nat. Protoc. 2014, 9, 1771–1791. [CrossRef]
29. Jermyn, M.; Mok, K.; Mercier, J.; Desroches, J.; Pichette, J.; Saint-Arnaud, K.; Bernstein, L.; Guiot, M.-C.;
Petrecca, K.; Leblond, F. Intraoperative brain cancer detection with Raman spectroscopy in humans. Sci. Transl.
Med. 2015, 7, 274ra19. [CrossRef]
Cancers 2020, 12, 3682 20 of 22
30. Desroches, J.; Jermyn, M.; Pinto, M.; Picot, F.; Tremblay, M.-A.; Obaid, S.; Marple, E.; Urmey, K.; Trudel, D.;
Soulez, G.; et al. A new method using Raman spectroscopy for in vivo targeted brain cancer tissue biopsy.
Sci. Rep. 2018, 8, 1792. [CrossRef]
31. Hollon, T.; Lewis, S.; Freudiger, C.W.; Sunney Xie, X.; Orringer, D.A. Improving the accuracy of brain tumor
surgery via Raman-based technology. Neurosurg. Focus 2016, 40, E9. [CrossRef]
32. Broadbent, B.; Tseng, J.; Kast, R.; Noh, T.; Brusatori, M.; Kalkanis, S.N.; Auner, G.W. Shining light on
neurosurgery diagnostics using Raman spectroscopy. J. Neurooncol. 2016, 130, 1–9. [CrossRef]
33. Beleites, C.; Steiner, G.; Sowa, M.G.; Baumgartner, R.; Sobottka, S.; Schackert, G.; Salzer, R. Classification of
human gliomas by infrared imaging spectroscopy and chemometric image processing. Vib. Spectrosc. 2005,
38, 143–149. [CrossRef]
34. Krafft, C.; Thümmler, K.; Sobottka, S.B.; Schackert, G.; Salzer, R. Classification of malignant gliomas by
infrared spectroscopy and linear discriminant analysis. Biopolymers 2006, 82, 301–305. [CrossRef] [PubMed]
35. Krafft, C.; Shapoval, L.; Sobottka, S.B.; Schackert, G.; Salzer, R. Identification of Primary Tumors of Brain
Metastases by Infrared Spectroscopic Imaging and Linear Discriminant Analysis. Technol. Cancer Res. Treat.
2006, 5, 291–298. [CrossRef]
36. Gajjar, K.; Heppenstall, L.D.; Pang, W.; Ashton, K.M.; Trevisan, J.; Patel, I.I.; Llabjani, V.; Stringfellow, H.F.;
Martin-Hirsch, P.L.; Dawson, T.; et al. Diagnostic segregation of human brain tumours using Fourier-transform
infrared and/or Raman spectroscopy coupled with discriminant analysis. Anal. Methods 2013, 5, 89–102.
[CrossRef] [PubMed]
37. Sala, A.; Anderson, D.J.; Brennan, P.M.; Butler, H.J.; Cameron, J.M.; Jenkinson, M.D.; Rinaldi, C.;
Theakstone, A.G.; Baker, M.J. Biofluid Diagnostics by FTIR Spectroscopy: A Platform Technology for
Cancer Detection. Cancer Lett. 2020, S0304383520300835. [CrossRef]
38. Cameron, J.M.; Butler, H.J.; Anderson, D.J.; Christie, L.; Confield, L.; Spalding, K.E.; Finlayson, D.; Murray, S.;
Panni, Z.; Rinaldi, C.; et al. Exploring pre-analytical factors for the optimisation of serum diagnostics:
Progressing the clinical utility of ATR-FTIR spectroscopy. Vib. Spectrosc. 2020, 109, 103092. [CrossRef]
39. Surowka, A.D.; Adamek, D.; Szczerbowska-Boruchowska, M. The combination of artificial neural networks
and synchrotron radiation-based infrared micro-spectroscopy for a study on the protein composition of
human glial tumors. Analyst 2015, 140, 2428–2438. [CrossRef]
40. Uckermann, O.; Juratli, T.A.; Galli, R.; Conde, M.; Wiedemuth, R.; Krex, D.; Geiger, K.; Temme, A.;
Schackert, G.; Koch, E.; et al. Optical Analysis of Glioma: Fourier-Transform Infrared Spectroscopy Reveals
the IDH1 Mutation Status. Clin. Cancer Res. 2018, 24, 2530–2538. [CrossRef]
41. Theophilou, G.; Morais, C.L.M.; Halliwell, D.E.; Lima, K.M.G.; Drury, J.; Martin-Hirsch, P.L.; Stringfellow, H.F.;
Hapangama, D.K.; Martin, F.L. Synchrotron- and focal plane array-based Fourier-transform infrared
spectroscopy differentiates the basalis and functionalis epithelial endometrial regions and identifies putative
stem cell regions of human endometrial glands. Anal. Bioanal. Chem. 2018, 410, 4541–4554. [CrossRef]
42. Marcelli, A.; Cinque, G. Chapter 3. Infrared Synchrotron Radiation Beamlines: High Brilliance Tools for
IR Spectromicroscopy. In RSC Analytical Spectroscopy Series; Moss, D., Ed.; Royal Society of Chemistry:
Cambridge, UK, 2010; pp. 67–104. ISBN 978-0-85404-154-1.
43. Miller, L.M.; Smith, R.J. Synchrotrons versus globars, point-detectors versus focal plane arrays: Selecting the
best source and detector for specific infrared microspectroscopy and imaging applications. Vib. Spectrosc.
2005, 38, 237–240. [CrossRef]
44. Szopa, W.; Burley, T.A.; Kramer-Marek, G.; Kaspera, W. Diagnostic and Therapeutic Biomarkers in
Glioblastoma: Current Status and Future Perspectives. BioMed Res. Int. 2017, 2017, 1–13. [CrossRef]
[PubMed]
45. Shankar, G.M.; Francis, J.M.; Rinne, M.L.; Ramkissoon, S.H.; Huang, F.W.; Venteicher, A.S.;
Akama-Garren, E.H.; Kang, Y.J.; Lelic, N.; Kim, J.C.; et al. Rapid Intraoperative Molecular Characterization
of Glioma. JAMA Oncol. 2015, 1, 662. [CrossRef] [PubMed]
46. Diamond Light Source MIRIAM B22 Beamline. Available online: https://www.diamond.ac.uk/B22 (accessed
on 10 March 2020).
47. Cinque, G.; Frogley, M.; Wehbe, K.; Filik, J.; Pijanka, J. Multimode InfraRed Imaging and Microspectroscopy
(MIRIAM) Beamline at Diamond. Synchrotron Radiat. News 2011, 24, 24–33. [CrossRef]
Cancers 2020, 12, 3682 21 of 22
48. Bassan, P.; Sachdeva, A.; Kohler, A.; Hughes, C.; Henderson, A.; Boyle, J.; Shanks, J.H.; Brown, M.;
Clarke, N.W.; Gardner, P. FTIR microscopy of biological cells and tissue: Data analysis using resonant Mie
scattering (RMieS) EMSC algorithm. Analyst 2012, 137, 1370. [CrossRef] [PubMed]
49. Toplak, M.; Birarda, G.; Read, S.; Sandt, C.; Rosendahl, S.M.; Vaccari, L.; Demšar, J.; Borondics, F. Infrared
Orange: Connecting Hyperspectral Data with Machine Learning. Synchrotron Radiat. News 2017, 30, 40–45.
[CrossRef]
50. Raschka, S. Linear Discriminant Analysis-Bit by Bit. Available online: https://sebastianraschka.com/Articles/
2014_python_lda.html (accessed on 10 March 2020).
51. Cameron, J.M.; Butler, H.J.; Smith, B.R.; Hegarty, M.G.; Jenkinson, M.D.; Syed, K.; Brennan, P.M.; Ashton, K.;
Dawson, T.; Palmer, D.S.; et al. Developing infrared spectroscopic detection for stratifying brain tumour
patients: Glioblastoma multiforme vs. lymphoma. Analyst 2019, 144, 6736–6750. [CrossRef]
52. Butler, H.J.; Brennan, P.M.; Cameron, J.M.; Finlayson, D.; Hegarty, M.G.; Jenkinson, M.D.; Palmer, D.S.;
Smith, B.R.; Baker, M.J. Development of high-throughput ATR-FTIR technology for rapid triage of brain
cancer. Nat. Commun. 2019, 10, 4501. [CrossRef]
53. Cameron, J.M.; Butler, H.J.; Palmer, D.S.; Baker, M.J. Biofluid spectroscopic disease diagnostics: A review on
the processes and spectral impact of drying. J. Biophotonics 2018, 11, e201700299. [CrossRef]
54. Lovergne, L.; Clemens, G.; Untereiner, V.; Lukaszweski, R.A.; Sockalingum, G.D.; Baker, M.J. Investigating
optimum sample preparation for infrared spectroscopic serum diagnostics. Anal. Methods 2015, 7, 7140–7149.
[CrossRef]
55. Lovergne, L.; Bouzy, P.; Untereiner, V.; Garnotel, R.; Baker, M.J.; Thiéfin, G.; Sockalingum, G.D. Biofluid
infrared spectro-diagnostics: Pre-analytical considerations for clinical applications. Faraday Discuss 2016,
187, 521–537. [CrossRef]
56. Cameron, J.M.; Rinaldi, C.; Butler, H.J.; Hegarty, M.G.; Brennan, P.M.; Jenkinson, M.D.; Syed, K.; Ashton, K.M.;
Dawson, T.P.; Palmer, D.S.; et al. Stratifying Brain Tumour Histological Sub-Types: The Application of
ATR-FTIR Serum Spectroscopy in Secondary Care. Cancers 2020, 12, 1710. [CrossRef] [PubMed]
57. Bassan, P.; Byrne, H.J.; Bonnier, F.; Lee, J.; Dumas, P.; Gardner, P. Resonant Mie scattering in infrared
spectroscopy of biological materials—Understanding the ‘dispersion artefact’. Analyst 2009, 134, 1586.
[CrossRef] [PubMed]
58. Viera, A.J.; Garrett, J.M. Understanding Interobserver Agreement: The Kappa Statistic. Fam. Med. 2005, 37,
360–363.
59. McHugh, M.L. Interrater reliability: The kappa statistic. Biochem. Med. 2012, 22, 276–282. [CrossRef]
60. Mandrekar, J.N. Receiver Operating Characteristic Curve in Diagnostic Test Assessment. J. Thorac. Oncol.
2010, 5, 1315–1316. [CrossRef] [PubMed]
61. Hajian-Tilaki, K. Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test
Evaluation. Casp. J. Intern. Med. 2013, 4, 627–635.
62. Smith, B.R.; Ashton, K.M.; Brodbelt, A.; Dawson, T.; Jenkinson, M.D.; Hunt, N.T.; Palmer, D.S.; Baker, M.J.
Combining random forest and 2D correlation analysis to identify serum spectral signatures for neuro-oncology.
Analyst 2016, 141, 3668–3678. [CrossRef]
63. Dumas, P.; Miller, L.M.; Tobin, M.J. Challenges in Biology and Medicine with Synchrotron Infrared Light.
Acta Phys. Pol. A 2009, 115, 446–454. [CrossRef]
64. Carr, G.L. Resolution limits for infrared microspectroscopy explored with synchrotron radiation. Rev. Sci.
Instrum. 2001, 72, 1613. [CrossRef]
65. Kaur, G.; Dufour, J.M. Cell lines: Valuable tools or useless artifacts. Spermatogenesis 2012, 2, 1–5. [CrossRef]
66. Kong, J.; Yu, S. Fourier Transform Infrared Spectroscopic Analysis of Protein Secondary Structures. Acta
Biochim. Biophys. Sin. 2007, 39, 549–559. [CrossRef] [PubMed]
67. Barth, A. Infrared spectroscopy of proteins. Biochim. Biophys. Acta BBA Bioenerg. 2007, 1767, 1073–1101.
[CrossRef] [PubMed]
68. Petricoin, E.F.; Belluco, C.; Araujo, R.P.; Liotta, L.A. The blood peptidome: A higher dimension of information
content for cancer biomarker discovery. Nat. Rev. Cancer 2006, 6, 961–967. [CrossRef]
69. Bonnier, F.; Baker, M.J.; Byrne, H.J. Vibrational spectroscopic analysis of body fluids: Avoiding molecular
contamination using centrifugal filtration. Anal. Methods 2014, 6, 5155. [CrossRef]
Cancers 2020, 12, 3682 22 of 22
70. Bonnier, F.; Petitjean, F.; Baker, M.J.; Byrne, H.J. Improved protocols for vibrational spectroscopic analysis of
body fluids: Improved protocols for vibrational spectroscopic analysis of body fluids. J. Biophotonics 2014, 7,
167–179. [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
affiliations.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
